GlassScriptPhysician profile
Michael D Nunez
NPI 1275686008
$7,012.82
in general payments reported to CMS, 2019-2025
46 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,846 · 2020: $472 · 2021: $358 · 2022: $758 · 2023: $1,052 · 2024: $870 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Entertainment: $26.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.31 |
| Entertainment | $26.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,617.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,178.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $447.15 | 2021-2025 | |
| Pfizer INC. | $380.65 | 2019-2025 | |
| Abbott Laboratories | $246.04 | 2021-2025 | Eterna, Proclaim, Octrode |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.19 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $219.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $193.81 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $162.34 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.16 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $100.87 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Janssen Pharmaceuticals, INC | $95.60 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $86.11 | 2019-2025 | |
| Saluda Medical Americas, INC. | $80.93 | 2025 | Evoke |
| Sanofi Pasteur INC. | $71.68 | 2019-2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $68.16 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $50.05 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $49.94 | 2021-2024 | Wegovy |
| Phadia US INC. | $41.58 | 2024-2025 | Immunocap |
| Boston Scientific Corporation | $40.66 | 2020-2022 | |
| Intra-Sana Laboratories | $36.78 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Almirall LLC | $36.62 | 2023 | Klisyri |
| Scilex Pharmaceuticals INC. | $36.60 | 2023 | Ztlido |
| Astellas Pharma US INC | $33.27 | 2023-2024 | Veozah |
| Optos, INC. | $26.02 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biohaven Pharmaceutical Holding Company LTD. | $25.38 | 2022 | |
| Collegium Pharmaceutical, INC. | $24.41 | 2025 | Xtampza |
| Amgen INC. | $24.11 | 2024 | Repatha, Otezla |
| Shire North American Group INC | $21.34 | 2019 | |
| Si-Bone, INC. | $20.96 | 2022 | |
| Strongbridge US INC. | $20.24 | 2020 | |
| Gilead Sciences, INC. | $19.75 | 2020 | |
| Mayne Pharma Commercial LLC | $19.44 | 2023 | |
| Corcept Therapeutics | $18.89 | 2025 | Korlym |
| Sun Pharmaceutical Industries INC. | $18.85 | 2024 | |
| Alfasigma USA, INC. | $16.58 | 2022 | |
| Leo Pharma INC. | $16.50 | 2022 | |
| Shield Therapeutics INC | $16.41 | 2023 | Accrufer |
| Neos Therapeutics, LP | $16.29 | 2023 | Adzenys Xr-Odt |
| Medtronic USA, INC. | $15.85 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.91 | 2024 | Nuzyra |
| Bardy Diagnostics, INC. | $14.83 | 2022 | |
| Nevro Corp. | $14.13 | 2023 | Senza |
| Organon LLC | $13.98 | 2021 | |
| Celgene Corporation | $13.25 | 2021 | |
| Esperion Therapeutics, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.